Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARTO: Spartalizumab and low-dose Pazopanib in Refractory or Relapsed Solid Tumors
2024-513535-24-00Phase 2Suspended
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Oct 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of pazopanib and spartalizumab in Nonhematologic neoplasms, Not applicable, Constitutional mismatch repair deficiency (CMMRD) and 3 more (2 cohorts), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoints: Maximum tolerated dose in pediatric cohort and 6-month disease control rate in adult cohort. Started Oct 2024; status: suspended.
02
Drugs
pazopanibspartalizumab
03
Conditions
Nonhematologic neoplasmsNot applicableConstitutional mismatch repair deficiency (CMMRD)osteosarcoma (OS)Ewing sarcoma
Beyond the preview
Go deeper on 2024-513535-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513535-24-00.